Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy

✍ Scribed by Khoo, Vincent S.; Pollack, Alan; Cowen, Didier; Joon, Daryl Lim; Patel, Nalini; Terry, Nicholas H.A.; Zagars, Gunar K.; von Eschenbach, Andrew C.; Meistrich, Marvin L.; Troncoso, Patricia

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 162 KB
• Volume: 41
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(19991101)41:3<166::aid-pros3>3.0.co;2-e

✦ Synopsis

BACKGROUND.

Our purpose was to evaluate the relationship of Ki-67 labeling index (Ki67-LI) to deoxyribonucleic acid (DNA) ploidy, S phase fraction (SPF), other clinical prognostic factors, and clinical outcome for patients with prostate cancer treated by external beam radiotherapy. METHODS. Tissue was retrieved from 42 patients who underwent transurethral resection of the prostate before treatment with external beam radiotherapy between 1987-1993. DNA histogram profiles were classified as diploid (diploid + near-diploid) and nondiploid (tetraploid + aneuploid). Immunohistochemical staining of Ki-67 by the MIB-1 monoclonal antibody was used to calculate Ki67-LI. Median patient follow-up was 62 months. Treatment failure was defined as two consecutive rises in serum prostate-specific antigen (PSA) or clinical evidence of disease recurrence. RESULTS. The mean and median Ki67-LIs were 3.1 and 2.4, respectively (range, 0-12.4). Mean Ki67-LI values were significantly associated with higher stage, Gleason score, and pretreatment PSA. Nondiploid tumors had significantly higher Ki67-LIs, as did patients who failed radiotherapy over the follow-up period. SPF was not significantly correlated with Ki67-LI. As a categorical variable, the most significant relationships were seen when Ki67-LI was subdivided into thirds around the median (Ki67-LI Յ1.5%, Ki67-LI >1.5-3.5%, and Ki67-